US83175M2052 - SNN - 939163 (XNYS)
SMITH+NEPHEW ADR5 DL-20/2 Hinterlegungsschein
24,43 USD
Aktuelle Kurse von SMITH+NEPHEW ADR5 DL-20/2
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NYSE |
SNN
|
USD
|
24.12.2024 19:00
|
24,43 USD
| 24,53 USD | -0,41 % |
Performance
Heute | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | -1,85 % | -3,36 % | -20,14 % | -2,71 % | -10,45 % | -49,02 % |
Firmenprofil zu SMITH+NEPHEW ADR5 DL-20/2 Hinterlegungsschein
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Unternehmensdaten SMITH+NEPHEW ADR5 DL-20/2 Hinterlegungsschein
Name SMITH+NEPHEW ADR5 DL-20/2
Firma Smith & Nephew plc
Symbol SNN
Website https://www.smith-nephew.com
Heimatbörse
NYSE
WKN 939163
ISIN US83175M2052
Wertpapierart Hinterlegungsschein
Sektor Healthcare
Branche Medical - Devices
CEO Dr. Deepak S. Nath Ph.D.
Marktkapitalisierung 13 Mrd.
Land Großbritannien und Nordirland
Währung USD
Mitarbeiter 18,0 T
Adresse Building 5, WD18 8YE Watford
IPO Datum 1999-11-16
Aktien-Splits
Datum | Split |
---|---|
15.10.2014 | 2499:1000 |
16.12.2003 | 2:1 |
07.08.2000 | 9:11 |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | NPWA.F |
NYSE | SNN |
Weitere Aktien
Investoren die SMITH+NEPHEW ADR5 DL-20/2 die halten, haben auch folgende Aktien im Depot:
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.